Actinogen Medical: Phase II XanADu Trial Results
Edison | May 09, 2019 02:17AM ET
Yesterday Actinogen (AX:ACW) announced the initial results from its Phase II clinical trial of Xanamem in patients with mild dementia due to Alzheimer’s disease (AD). The safety of the drug was confirmed and the data showed Xanamem was effectively inhibiting cortisol production, as demonstrated by the expected increase in adrenocorticotropic hormone. However, the 10mg dose of Xanamem was not effective in demonstrating statistical significance on any of the endpoints. We note that both primary and secondary endpoints were robust ‘gold standard’ psychiatric tests used to measure cognition in AD patients, hence the trial was well designed, but the hurdle was high. Actinogen indicated it will analyse the data and make a decision on future steps once that is complete and the results from other supporting trials are released. Specifically, the company indicated that a higher dose and longer treatment could potentially be a way forward, given the drug appears safe and pharmacologically active.
Xanamem is a selective 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor that can cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in AD (described in detail in our initiation report). The Phase II XanADu trial started in March 2017. It was a double-blind, placebo-controlled Phase II trial with mild AD patients (n=186), who received 10mg of Xanamem daily or placebo (1:1) for 12 weeks. Primary endpoints included ADAS-Cog v14 and ADCOMS. Secondary endpoints included RAVLT, CDR-SOB, MMSE, NPI and NTB.
All these endpoints are robust measures of cognition in AD trials and we believe the design of the trial was sound. Actinogen indicated it will conduct detailed analysis of the data, looking for potential trends. In addition, Actinogen is close to reporting data from its target occupancy and XanaHES higher dose (20mg and 30mg) safety studies. The company expects the insights from these and the XanADu studies will allow the design of a path forward for Xanamem. For example, this could be a longer treatment study with higher dosing. Initial XanaHES results are expected by end of June 2019, when there could be more clarity on the future of Xanamem. For the time being, our forecasts and valuation is under review.
Get The News You Want
Business description
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. The primary indication is cognitive impairment in mild AD patients and results from the ongoing Phase II XanADu trial are expected to be announced Q219.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.